A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
ConditionCarcinoma, Non-Small-Cell Lung
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHunan Cancer Hospital
About this trial
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
Eligibility criteria
Qualifiers
None
Disqualifiers
Histologically or cytologically confirmed mixed SCLC and NSCLC;
Subjects with driver gene mutations(EGFR mutation, ALK fusion, etc.);
Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC;
Previous thoracic radiotherapy;
Trial design
Treatments tested in this trial
- Sugemalimab and Chemotherapy
Treatment groups
41 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov